Современная ревматология (Sep 2018)

Methotrexate in the combination therapy of juvenile idiopathic arthritis

  • E. S. Zholobova,
  • М. N. Nikolaeva,
  • S. N. Chebysheva,
  • A. V. Meleshkina,
  • O. Yu. Loskutova,
  • L. A. Galstyan,
  • E. Yu. Afonina

DOI
https://doi.org/10.14412/1996-7012-2018-3-98-102
Journal volume & issue
Vol. 12, no. 3
pp. 98 – 102

Abstract

Read online

The paper discusses whether biological agents (BAs) may be used as monotherapy. The combination of different BAs and methotrexate (MTX) allows a good result in patients with juvenile idiopathic arthritis refractory to standard antirheumatic therapy. The efficiency of this therapy meets the ACRpedi50 criteria in 80–90% of patients; one third of patients can achieve the inactive stage of the disease. When BAs are administered, the frequency of use of nonsteroidal anti-inflammatory drugs and glucocorticoids is reduced. In only 15% of patients, MTX can be discontinued during the first year of therapy with BA, significantly more frequently with tocilizumab.

Keywords